Analyst Price Target is $38.25
▲ +191.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for iTeos Therapeutics in the last 3 months. The average price target is $38.25, with a high forecast of $54.00 and a low forecast of $32.00. The average price target represents a 191.10% upside from the last price of $13.14.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in iTeos Therapeutics.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.